伊立替康联合雷替曲塞3周方案二线治疗晚期结直肠癌的疗效观察

李玉梅; 刘静; 赵福友; 周争光; 吴穷

doi:10.13898/j.cnki.issn.1000-2200.2017.08.005

伊立替康联合雷替曲塞3周方案二线治疗晚期结直肠癌的疗效观察

蚌埠医学院第一附属医院肿瘤内科, 安徽蚌埠 233004

作者简介: 李玉梅(1983-),女,硕士,主治医师.

基金项目:
蚌埠医学院自然科学基金资助项目（Byky1331）
中图分类号: R735.35

Clinical observation of the 3-week schedule of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer

Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu Anhui 233004, China
CLC number: R735.35

摘要: 目的：观察伊立替康联合雷替曲塞二线治疗晚期结直肠癌的疗效及安全性。方法：对22例一线治疗失败的晚期结直肠癌病人予以二线治疗：伊立替康180 mg/m²，静脉滴注1 h，第1天；雷替曲塞3 mg/m²，静脉滴注15 min，第2天；21 d为1个周期。每2个周期评价疗效，并分析其安全性。结果：22例病人均可评价近期疗效，其中完全缓解1例，部分缓解4例，疾病稳定11例，疾病进展6例，客观有效率为22.7%，疾病控制率为72.7%，病人的中位肿瘤进展时间为5.0个月，中位总生存时间11.8个月。严重不良反应为中性粒细胞减少和腹泻，发生率分别为13.6%和4.5%。结论：伊立替康联合雷替曲塞在晚期结直肠癌的二线化疗中，有效率较高，不良反应能够耐受，值得在临床上推广。
- 结直肠肿瘤 /
- 雷替曲塞 /
- 伊立替康 /
- 化学治疗
Abstract: Objective:To observe the efficacy and safety of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer.Methods:Twenty-two patients with advanced colorectal cancer were treated with the second-line chemotherapy after the first-line treatment failure.The patients were treated with 180 mg/m² of irinotecan by intravenous infusion for 1 h on the first day,and 3 mg/m² of raltitrexed by intravenous infusion for 15 minutes on the second day,21 days as a cycle.The efficacy and safety were evaluated every 2 cycles.Results:The short-term efficacy of all cases was evaluated.The complete response in 1 case,partial response in 4 cases,stable disease in 11 cases and progressive disease in 6 cases were found.The objective response and disease control rates were 22.7% and 72.7%,respectively.The median time of tumor progression and median overall survival time were 5.0 and 11.8 months,respectively.The neutrophilopenia and diarrhea were serious adverse reactions,the incidence rates of those were 13.6% and 4.5%,respectively.Conclusions:The irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer is high efficacy,and the adverse reactions can be tolerated,which is worthy of wider application.
- colorectal neoplasms /
- raltitrexed /
- irinotecan /
- chemotherapy

[1]	吴菲,林国帧,张晋昕.我国恶性肿瘤发病现状及趋势[J].中国肿瘤,2012,21(2):81.
[2]	HURWITZ HI,FEHRENBACHER L,HAINSORTH JD,et al.Bevacizumab in combination with fluorouracil and leucovorin:an active regimen for first-line metastatic colorectal cancer[J].J Clin Oncol,2005,23(15):3502.
[3]	GIANTONIO BJ,CATALANO PJ,MEROPOL NJ,et al.Bevacizumab in combination with oxaliplatin,fluorouracil,and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group Study E3200[J].J Clin Oncol,2007,25(12):1539.
[4]	HONG YS,KIM HJ,PARK SJ,et al.Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS[J].Cancer Sci,2013,104(4):473.
[5]	SOBRERO AF,MAUREL J,FEHRENBACHER L,et al.EPIC:phase Ⅲ trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer[J].J Clin Oncol,2008,26(14):2311.
[6]	PEETERS M,PRICE TJ,CERVANTRS A,et al.Randomized phase Ⅲ study of panitumumab with fluorouracil,leucovorin,and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer[J].J Clin Oncol,2010,28(31):4706.
[7]	WALDMAN BC,WANG Y,KILARU K,et al.Induction of intrachromosomal homologous recombination in human cells by raltitrexed,an inhibitor of thymidylate synthase[J].DNA Repair,2008,7(10):1624.
[8]	WILSON KS,MALFAIR TAYLOR SC.Raltitrexed:optimism and reality[J].Expert Opin Drug MetabToxicol,2009,5(11):1447.
[9]	MAUGHAN TS,JAMES RD,KERR DJ,et al.Comparison of survival,palliation,and quality of life with three chemotherapy regimens in metastatic colorectal cancer:a multicentre randomised trial[J].Lancet,2002,359(9317):1555.
[10]	ASCHELE C,BALDO C,SOBRERO AF,et al.Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro[J].Clin Cancer Res,1998,4(5):1323.
[11]	CHIARA S,NOBILE MT,TOMASELLO L,et al.Phase Ⅱ trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer[J].Anticancer Res,2005,25(2B):1391.
[12]	FELIU J,CASTANON C,SALUD A,et al.Phase Ⅱ randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer[J].Br J Cancer,2005,93(11):1230.
[13]	谢达成,李宁,王静珏,等.雷替曲塞联合伊立替康2周方案对比FOLFIRI方案二线治疗晚期结直肠癌的疗效观察[J].临床肿瘤学杂志,2013,18(2):140.
[14]	GALLAGHER DJ,KEMENY N.Metastatic colorectal cancer:from improved survival to potential cure[J].Oncology,2010,78(3/4):237.
[15]	周建红,李桂生,李高峰,等.伊立替康联合雷替曲塞在晚期结直肠癌二线化疗中的疗效及安全性研究[J].中国全科医学,2013,16(2B):555.

[1]	苏方 , 张甜甜 , 吴骁 , 汪蕊 , 汪子书 . 雷替曲塞及其联合奥沙利铂或伊立替康治疗晚期结直肠癌对转氨酶的影响. 蚌埠医学院学报, 2019, 44(9): 1194-1196, 1201. doi: 10.13898/j.cnki.issn.1000-2200.2019.09.014
[2]	刘静 , 刘杨 , 赵福友 , 汪蕊 , 李玉梅 . UGT1A1基因多态性与伊立替康治疗晚期胃肠道肿瘤不良反应和疗效的相关性分析. 蚌埠医学院学报, 2017, 42(8): 1017-1021. doi: 10.13898/j.cnki.issn.1000-2200.2017.08.002
[3]	崔红青 . 伊立替康联合顺铂治疗晚期肺癌护理体会. 蚌埠医学院学报, 2011, 36(5): 527-528.
[4]	孙翠玲 , 胡文军 . 伊立替康联合氟尿嘧啶/亚叶酸钙治疗晚期大肠癌疗效分析. 蚌埠医学院学报, 2010, 35(5): 459-460.
[5]	韩啸 , 张竞竞 , 王洪亚 , 韩正全 . 雷替曲塞或氟尿嘧啶联合吉西他滨治疗晚期乳腺癌的疗效比较. 蚌埠医学院学报, 2013, 37(8): 946-947,950.
[6]	张贡献 , 杨洋 . 奥沙利铂甘露醇联合雷替曲塞在老年晚期胃癌中的疗效观察. 蚌埠医学院学报, 2015, 40(8): 1011-1013. doi: 10.13898/j.cnki.issn.1000-2200.2015.08.008
[7]	邓玲慧 , 朱麒 , 金丽艳 , 张华 . 培美曲塞联合顺铂二线治疗未手术晚期胃癌病人的临床观察. 蚌埠医学院学报, 2019, 44(10): 1358-1361. doi: 10.13898/j.cnki.issn.1000-2200.2019.10.018
[8]	高小芳 . 腹腔镜联合结肠镜治疗结直肠肿瘤23例护理体会. 蚌埠医学院学报, 2012, 36(12): 1538-1539.
[9]	魏可 , 王文锐 , 杨清玲 , 陈昌杰 . 肿瘤相关巨噬细胞在结直肠癌发展及治疗和预后中的作用. 蚌埠医学院学报, 2023, 48(1): 31-36. doi: 10.13898/j.cnki.issn.1000-2200.2023.01.007
[10]	栾大明 , 胡宗宇 . 综合治疗结直肠癌肝转移68例. 蚌埠医学院学报, 2012, 36(1): 65-66.
[11]	郑玉强 , 戚良碧 , 房守军 . 结直肠癌致大肠梗阻外科治疗56例分析. 蚌埠医学院学报, 2009, 34(12): 1083-1084.
[12]	缪文忠 , 荣国强 , 黄凯平 . 结直肠癌伴急性梗阻48例的外科治疗. 蚌埠医学院学报, 2006, 31(6): 641-642.
[13]	陈涛 . 左半结肠及直肠癌性梗阻45例治疗体会. 蚌埠医学院学报, 2006, 31(6): 652-653.
[14]	蒋祥德 , 王磊 , 刘友如 , 施朕善 , 徐莹 . 卡培他滨联合奥沙利铂、多西他赛一线治疗晚期胃癌临床观察. 蚌埠医学院学报, 2014, 38(4): 471-473.
[15]	陈洁 . 局部晚期乳腺癌术后同步放化疗及序贯治疗疗效比较. 蚌埠医学院学报, 2015, 40(12): 1693-1695. doi: 10.13898/j.cnki.issn.1000-2200.2015.12.027
[16]	张成斌 , 周少波 , 邵明 , 郑兆炜 , 闻静 . 色素内镜联合肿瘤标志物检测在早期结直肠癌诊断中的应用. 蚌埠医学院学报, 2018, 43(1): 23-26. doi: 10.13898/j.cnki.issn.1000-2200.2018.01.007
[17]	陈广业 , 杨清 . 肿瘤坏死因子受体相关因子4在结直肠癌中的表达及临床意义. 蚌埠医学院学报, 2022, 47(3): 322-326. doi: 10.13898/j.cnki.issn.1000-2200.2022.03.012
[18]	杨尊敬 , 杜先玲 . 转移相关蛋白2对结直肠癌病人预后判断的价值. 蚌埠医学院学报, 2017, 42(9): 1186-1189. doi: 10.13898/j.cnki.issn.1000-2200.2017.09.010
[19]	年峰 , 袁圆 , 王海涛 , 芦华丽 . 结直肠癌组织中BRMS1 mRNA的表达及意义. 蚌埠医学院学报, 2018, 43(5): 614-616,620. doi: 10.13898/j.cnki.issn.1000-2200.2018.05.015
[20]	胡世丰 , 雷春 , 施炜 , 查诚 . LncRNA-ROR抑制结直肠癌细胞转移的作用研究. 蚌埠医学院学报, 2020, 45(5): 569-571,577. doi: 10.13898/j.cnki.issn.1000-2200.2020.05.003

点击查看大图

计量

文章访问数: 4983
HTML全文浏览量: 1115
PDF下载量: 66
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

伊立替康联合雷替曲塞3周方案二线治疗晚期结直肠癌的疗效观察

作者简介: 李玉梅(1983-),女,硕士,主治医师.

Clinical observation of the 3-week schedule of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer

计量

伊立替康联合雷替曲塞3周方案二线治疗晚期结直肠癌的疗效观察

作者简介: 李玉梅(1983-),女,硕士,主治医师.

English Abstract

Clinical observation of the 3-week schedule of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer

全文HTML

目录

留言板

伊立替康联合雷替曲塞3周方案二线治疗晚期结直肠癌的疗效观察

作者简介: 李玉梅(1983-),女,硕士,主治医师.

Clinical observation of the 3-week schedule of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer

计量

出版历程

伊立替康联合雷替曲塞3周方案二线治疗晚期结直肠癌的疗效观察

作者简介: 李玉梅(1983-),女,硕士,主治医师.

English Abstract

Clinical observation of the 3-week schedule of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer

全文HTML

目录